Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: Insights from the HEAAL study

International Journal of Cardiology

Volumn 173, Issue 3, 2014, Pages 380-387

  Rossignol, P ^a,b,c   Dobre, D ^a,b,c   Gregory, D ^d   Massaro, J ^e   Kiernan, M ^f   Konstam, M A ^f   Zannad, F ^a,b,c  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c INSERM UMR S 1116 University of Lorraine   (France)

^d Cardiovascular Clinical Studies   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

Heart failure; Hyperkalemia; Losartan; Renal insufficiency

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; LOSARTAN; POTASSIUM; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

AGE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TOLERANCE; ESTIMATED GLOMERULUS FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERKALEMIA; INCIDENCE; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FOLLOW UP; HEART STROKE VOLUME; INTERNATIONAL COOPERATION; MULTICENTER STUDY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPERKALEMIA; INCIDENCE; INTERNATIONALITY; LOSARTAN; MALE; RENAL INSUFFICIENCY; RISK FACTORS; STROKE VOLUME;

EID: 84899500566     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.02.034     Document Type: Article

References (27)

1. M.A. Konstam, J.D. Neaton, and K. Dickstein et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial Lancet 374 2009 1840 1848
2. A.S. Desai, K. Swedberg, and J.J. McMurray et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the charm program J Am Coll Cardiol 50 2007 1959 1966
3. G.L. Smith, J.H. Lichtman, and M.B. Bracken et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis J Am Coll Cardiol 47 2006 1987 1996
4. K. Damman, G. Navis, and A.A. Voors et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis J Card Fail 13 2007 599 608
5. D.N. Juurlink, M.M. Mamdani, and D.S. Lee et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study N Engl J Med 351 2004 543 551
6. M.R. Weir, and M. Rolfe Potassium homeostasis and renin-angiotensin- aldosterone system inhibitors Clin J Am Soc Nephrol 5 2010 531 548
7. B.F. Palmer Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 2004 585 592
8. S.A. Hunt, W.T. Abraham, and M.H. Chin et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 2009 e1 e90
9. F. Zannad, W. Gattis Stough, and P. Rossignol et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice Eur Heart J 33 2012 2782 2795
10. M.A. Konstam, P.A. Poole-Wilson, and K. Dickstein et al. Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ace-inhibitor Eur J Heart Fail 10 2008 899 906
11. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group Ann Intern Med 130 1999 461 470
12. I.S. Anand, K. Bishu, T.S. Rector, A. Ishani, M.A. Kuskowski, and J.N. Cohn Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure Circulation 120 2009 1577 1584
13. P. Rossignol, J.G. Cleland, and S. Bhandari et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study Circulation 125 2012 271 279
14. J. Ahmed, and L.S. Weisberg Hyperkalemia in dialysis patients Semin Dial 14 2001 348 356
15. R.A. Preston, D. Afshartous, D. Garg, S. Medrano, A.B. Alonso, and R. Rodriguez Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease Hypertension 53 2009 754 760
16. P. Jose, H. Skali, and N. Anavekar et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction J Am Soc Nephrol 17 2006 2886 2891
17. N.S. Anavekar, J.J. McMurray, and E.J. Velazquez et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction N Engl J Med 351 2004 1285 1295
18. O. Vardeny, D.H. Wu, and A. Desai et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from rales (randomized aldactone evaluation study) J Am Coll Cardiol 60 2012 2082 2089
19. B.M. Massie, C.M. O'Connor, and M. Metra et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure N Engl J Med 363 2010 1419 1428
20. A. Davenport, S.D. Anker, and A. Mebazaa et al. Adqi 7: The clinical management of the cardio-renal syndromes: Work group statements from the 7th adqi consensus conference Nephrol Dial Transplant 25 7 2010 2077 2089
21. P. Rossignol, and F. Zannad Loop diuretics and ultrafiltration in heart failure Expert Opin Pharmacother 14 2013 1641 1648
22. B. Pitt, G. Bakris, L.M. Ruilope, L. DiCarlo, and R. Mukherjee Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS) Circulation 118 2008 1643 1650
23. A. Desai Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit Circulation 118 2008 1609 1611
24. C.W. Yancy, M. Jessup, and B. Bozkurt et al. 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 62 16 2013 e147 e239
25. B. Pitt, W. Remme, and F. Zannad et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
26. F. Zannad, J.J. McMurray, and H. Krum et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
27. T.D. Smilde, D.J. van Veldhuisen, G. Navis, A.A. Voors, and H.L. Hillege Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction Circulation 114 2006 1572 1580